Retracted: Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial

Publisher Website
Google Scholar
Abstract
Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization‐induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2‐year follow‐up period was studied. At baseline, both groups of patients had low BMD with high levels of serum‐ionized calcium and urinary deoxypyridinoline (D‐Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10–0.85). The number of hip fracture per 1,000 patient‐years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D‐Pyr levels decreased significantly during the follow‐up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures. © 2006 Movement Disorder Society